| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypoalphalipoproteinemias | D052456 | 5 associated lipids |
| Renal Artery Obstruction | D012078 | 8 associated lipids |
| Death, Sudden, Cardiac | D016757 | 12 associated lipids |
| Blood Platelet Disorders | D001791 | 12 associated lipids |
| Cerebral Hemorrhage | D002543 | 13 associated lipids |
| Polycythemia Vera | D011087 | 13 associated lipids |
| Atrial Fibrillation | D001281 | 16 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Cerebrovascular Disorders | D002561 | 25 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Asthma | D001249 | 52 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
11-dehydro-txb2
Cross Reference
Introduction
To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 11-dehydro-txb2?
11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2
PubChem Associated disorders and diseases
What pathways are associated with 11-dehydro-txb2
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
What functions are associated with 11-dehydro-txb2?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
What genes are associated with 11-dehydro-txb2?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 11-dehydro-txb2
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yamanaka S et al. | 11-Dehydro thromboxane B2: a reliable parameter of thromboxane A2 production in dogs. | 1993 | Prostaglandins | pmid:8484010 |
| Westlund P et al. | Identification of 11-dehydro-TXB2 as a suitable parameter for monitoring thromboxane production in the human. | 1986 | Prostaglandins | pmid:3755250 |
| Kumlin M and Granström E | Radioimmunoassay for 11-dehydro-TXB2: a method for monitoring thromboxane production in vivo. | 1986 | Prostaglandins | pmid:3823488 |
| Chiabrando C et al. | Urinary excretion and origin of 11-dehydro-2,3-dinor-thromboxane B2 in man. | 1993 | Prostaglandins | pmid:8321910 |
| Seyberth HW et al. | Excretion of primary prostanoids and their metabolites during acute volume expansion. | 1988 | Prostaglandins | pmid:3163156 |
| Westlund P et al. | Circulating and urinary thromboxane B2 metabolites in the rabbit: 11-dehydro-thromboxane B2 as parameter of thromboxane production. | 1986 | Prostaglandins | pmid:3520685 |
| Chiabrando C et al. | Urinary excretion of 2,3-dinor-thromboxane B1, a major metabolite of thromboxane B2 in the rat. | 1994 | Prostaglandins | pmid:7938613 |
| d'Emmanuele di Villa Bianca R et al. | Hydrogen sulphide pathway contributes to the enhanced human platelet aggregation in hyperhomocysteinemia. | 2013 | Proc. Natl. Acad. Sci. U.S.A. | pmid:24019484 |
| McAdam BF et al. | Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. | 1999 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9874808 |
| Catella F et al. | 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. | 1986 | Proc. Natl. Acad. Sci. U.S.A. | pmid:3461463 |
| Montine TJ et al. | Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. | 2010 | PLoS ONE | pmid:20174466 |
| Gremmel T et al. | Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. | 2011 | Platelets | pmid:21231857 |
| Hart RG et al. | Aspirin dosage and thromboxane synthesis in patients with vascular disease. | 2003 | Pharmacotherapy | pmid:12741431 |
| Saareks V et al. | Opposite effects of nicotinic acid and pyridoxine on systemic prostacyclin, thromboxane and leukotriene production in man. | 2002 | Pharmacol. Toxicol. | pmid:12403056 |
| Patrignani P et al. | Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. | 2008 | Pharmacogenet. Genomics | pmid:18551041 |
| Heistein LC et al. | Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. | 2008 | Pediatr Cardiol | pmid:17896127 |
| DeFilippis AP et al. | Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity. | 2014 | Nutr Metab Cardiovasc Dis | pmid:24370448 |
| Mizugaki M | [Microdetermination of eicosanoids using mass spectrometry]. | 2000 | Nippon Yakurigaku Zasshi | pmid:10876809 |
| Frost-Pineda K et al. | Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. | 2011 | Nicotine Tob. Res. | pmid:21330277 |
| McConnell JP et al. | Urinary 11-dehydro-thromboxane B(2) and coagulation activation markers measured within 24 h of human acute ischemic stroke. | 2001 | Neurosci. Lett. | pmid:11684346 |
| Ciabattoni G et al. | Determinants of platelet activation in Alzheimer's disease. | 2007 | Neurobiol. Aging | pmid:16442186 |
| Davì G et al. | Thromboxane biosynthesis and platelet function in type II diabetes mellitus. | 1990 | N. Engl. J. Med. | pmid:2345567 |
| Fitzgerald DJ et al. | Platelet activation in unstable coronary disease. | 1986 | N. Engl. J. Med. | pmid:3531859 |
| Alessandrini P et al. | Thromboxane biosynthesis and platelet function in type I diabetes mellitus. | 1988 | N. Engl. J. Med. | pmid:3292913 |
| Christman BW et al. | An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. | 1992 | N. Engl. J. Med. | pmid:1603138 |
| Geske FJ et al. | AspirinWorks: a new immunologic diagnostic test for monitoring aspirin effect. | 2008 | Mol Diagn Ther | pmid:18288882 |
| Ciabattoni G et al. | Radioimmunoassay of 11-dehydrothromboxane B2. | 1990 | Meth. Enzymol. | pmid:2233352 |
| Fitzgerald DJ et al. | Thromboxane A2 synthesis in pregnancy-induced hypertension. | 1990 | Lancet | pmid:1969511 |
| Urinary thromboxane metabolites in pre-eclampsia. | 1990 | Lancet | pmid:1971907 | |
| Van Geet C et al. | Possible platelet contribution to pathogenesis of transient neonatal hyperammonaemia syndrome. | 1991 | Lancet | pmid:1670726 |
| Malini PL et al. | Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. | 1997 | Lancet | pmid:9217714 |
| Tönshoff B et al. | Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome. | 1990 | Kidney Int. | pmid:2111418 |
| Kapłon-Cieślicka A et al. | Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes. | 2013 | Kardiol Pol | pmid:24065375 |
| Davì G et al. | Platelet activation in obese women: role of inflammation and oxidant stress. | 2002 Oct 23-30 | JAMA | pmid:12387653 |
| Mills JL et al. | Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. | 1999 | JAMA | pmid:10432033 |
| Fritsma GA et al. | Monitoring the antiplatelet action of aspirin. | 2001 | JAAPA | pmid:11523339 |
| Thomason J et al. | Platelet cyclooxygenase expression in normal dogs. | 2011 Sep-Oct | J. Vet. Intern. Med. | pmid:21985141 |
| Dudley A et al. | Cyclooxygenase expression and platelet function in healthy dogs receiving low-dose aspirin. | 2013 Jan-Feb | J. Vet. Intern. Med. | pmid:23278865 |
| Lin JS et al. | The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F1 alpha in arteriogenic impotence. | 1992 | J. Urol. | pmid:1635125 |
| Hartanto MD et al. | Urinary 11-dehydro-thromboxane Bâ‚‚ and 2,3-dinor-6-keto-prostaglandin-Fâ‚α in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg. | 2012 | J. Thromb. Thrombolysis | pmid:22311294 |
| Addad F et al. | Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease. | 2010 | J. Thromb. Thrombolysis | pmid:19381450 |
| Olson MT et al. | Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. | 2012 | J. Thromb. Haemost. | pmid:23072449 |
| Ferroni P et al. | Platelet activation in type 2 diabetes mellitus. | 2004 | J. Thromb. Haemost. | pmid:15304032 |
| Ohmori T et al. | Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. | 2006 | J. Thromb. Haemost. | pmid:16706971 |
| De Cristofaro R et al. | Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. | 2003 | J. Thromb. Haemost. | pmid:12871497 |
| Li C et al. | Reversal of the anti-platelet effects of aspirin and clopidogrel. | 2012 | J. Thromb. Haemost. | pmid:22268852 |
| Lemkes BA et al. | The influence of aspirin dose and glycemic control on platelet inhibition in patients with type 2 diabetes mellitus. | 2012 | J. Thromb. Haemost. | pmid:22252020 |
| Santilli F et al. | Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. | 2010 | J. Thromb. Haemost. | pmid:20088941 |
| Maga P et al. | 11-dehydro thromboxane B2 levels after percutaneous transluminal angioplasty in patients with peripheral arterial occlusive disease during a one year follow-up period. | 2016 | J. Physiol. Pharmacol. | pmid:27511998 |
| Catella-Lawson F et al. | Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. | 1999 | J. Pharmacol. Exp. Ther. | pmid:10215647 |